Author + information
Endothelial damage plays an important role in early pathogenesis of atherosclerosis. This adhesion is mediated by intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and omentin-1. The aims of this study were to investigate the effects of ticagrelor to those serum intercellular adhesions in atherosclerosis hemodialysis patients.
Starting from November 2012, a cohort of 2015 atherosclerosis HD patients participated in this 3-year follow-up study. The subjects were divided into four groups according to the presence of atherosclerosis: ticagrelor-treatment atherosclerosis HD patients, clopidogrel-treatment atherosclerosis HD patients, control atherosclerosis HD patients and HD patients. Atherosclerotic disease was assessed by measuring carotid intima-media thickness (IMT) and serum levels of low density lipoprotein(LDL). Samplings were collected at baseline and thereafter every 1 year until the end of follow-up.
Ticagrelor and clopidogrel did not decreased serum total Cholesterol(TC), triglyceride(TG), high-density lipoproteincholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) levels of atherosclerosis HD patients. The resum levels of sICAM-1,omentin-1 and sVCAM-1 of atherosclerosis HD patients were more than those of HD patients. Ticagrelor could decrease the serum levels of sICAM-1 and omentin-1 in the atherosclerosis HD patients more than clopidogrel -treatment atherosclerosis HD patients and atherosclerosis HD patients, but there were no difference between the other two patients groups. There were no differences of serum levels of sVCAM-1 among the three atherosclerosis HD patients. Ticagrelor could decrease the cardiovascular death and retard the IMT progression of atherosclerosis HD patients, but clopidogrel could not have the effects.
Our study demonstrated that ticagrelor could decrease the serum levels of sICAM-1 and omentin-1 in atherosclerosis HD patients and retarded the progression of atherosclerosis.